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Background: ABCG2, also known as BCRP, is a half ATP-binding cassette (ABC) transporter that localizes to plasma
membranes. Recently, a number of studies have investigated the relationship between the C421A polymorphism in
ABCG2 and cancer risk in multiple populations and various types of cancers; however, this relationship remains
unclear. Therefore, we performed a meta-analysis to further explore this association.
Methods: The meta-analysis incorporated 10 studies involving a total of 3593 cases and 5875 controls. Odds ratios (ORs)
and 95% confidence intervals (CIs) were calculated based on the date extracted from the studies to evaluate the strength
of association. We also analyzed the heterogeneity and sensitivity of each report and the publication bias of the studies.
Results: Overall, our results showed that there appeared to be a significant association between the ABCG2 C421A
polymorphism and decreased cancer susceptibility (heterozygote-AC versus CC: OR=0.759, 95%CI = 0.620-0.930;
dominant effects model-AA/AC versus CC: OR=0.771, 95%CI = 0.634-0.938; additive effects model-A allele versus C allele:
OR=0.809, 95%CI = 0.687-0.952). Similarly, decreased cancer risk was also found after stratification of the SNP data by
cancer type, ethnicity and source of controls in heterozygote model, dominant effects model and additive effects model.
Conclusions: We found that the ABCG2 C421A polymorphism is a protective factor for developing cancer. The same
relationship was found when the studies were stratified by cancer type, ethnicity and source of controls.Background
Cancer is a multi-factorial disease, which results from
complex interactions between environmental and genetic
factors, has become one of the most challenging health
issues today [1]. In contrast to environmental variables,
the genetic variables ranging from single-nucleotide sub-
stitutions to major chromosomal aberrations may make
more contribution to the cancer development [2,3]. In
the last few years, an increasing number of studies have
been conducted to assess the relationship between the
hereditary factors and cancer risk.
ABC transporters, or the family of adenosine triphos-
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reproduction in any medium, provided the ortransmembrane glycoprotein and contain over 50 mem-
bers which can mediate the transfer of a wide variety of
substrates across cellular membranes [4]. ATP-binding
cassette G2 (ABCG2), originally known as Breast Can-
cer Resistant Protein (BCRP), first discovered in
doxorubicin-resistant breast cancer cells is a major
member of the ATP-binding cassette transporter family
and located on chromosomal region 4q22 encoding a
72-kDa membrane protein [5,6]. It is constitutively
expressed in various tissues such as the embryonic stem
cells, placental syncytiotrophoblasts, pancreas, liver,
gastrointestinal, muscle and immature hematopoietic tis-
sues [7-9]. Previous functional researches reviewed that
ABCG2 can transport a wide spectrum of substrates,
ranging from chemotherapeutic agents to carcinogenic
xenobiotics [10-13]. ABCG2 may play an important role
in controlling the cellular export of xenobiotic mole-
cules. The differential metabolism of xenobiotics due totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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risk of some cancers [14-18].
It has been recognized that single nucleotide poly-
morphisms (SNPs) are the most common inherited se-
quence variations in the human genome. These
polymorphisms can change the expression and activity
of the corresponding genes and their proteins and affect
the susceptibility to different types of cancers [19-23].
Researches had shown that there were two frequently
polymorphic SNPs in the BCRP gene: one in exon2
(G34A, resulting in a V12M change) and the other in
exon5 (C421A, resulting in a Q141K substitution) re-
spectively [15]. The C421A polymorphism (rs2231142)
in ABCG2 which lead to a glutamine-to-lysine amino
acid substitution is found at different frequencies in dif-
ferent ethnic populations (Asians: 35%, Caucasians: 10%)
and is apparently correlated with the reduced expression
and activity of BCRP protein [21,24-26].
To date, numerous studies have investigated the associ-
ation between the C421A polymorphism in ABCG2 and
the cancer susceptibility. Unfortunately, however, the
results of these studies have been inconsistent. Therefore,
in order to gain insights into the association between poly-
morphism of ABCG2 C421A and cancer risk, we con-
ducted a meta-analysis of eligible case–control and cohort
studies.
Methods
Study eligibility and validity assessment
We conducted a systematic search in PubMed and
Embase (last updated on February 10, 2012) using the
terms "(ABCG2 or BCRP) and polymorphism "without
any restriction in language and publication year. To
identify other relevant studies, the articles cited by the
retrieved studies were also searched. Each of the selected
articles in our meta-analysis met all of the following cri-
teria: 1) the article pertained to the ABCG2 C421A poly-
morphism and cancer risk; 2) the design was a human
case–control or case-cohort study; and 3) the genotype
frequencies in the cancer cases and controls were avail-
able. Studies were excluded if they did not include a
control population, did not determine genotype fre-
quency and or were duplicates of previous publications.
Data extraction
The data were extracted from all eligible studies that
met the selection criteria listed above. The data extrac-
tion was performed by two authors independently and
any disagreements were resolved by discussion between
the two authors. The data collected from each study
were as follows: the first author's name, publication year,
country of origin, ethnicity, cancer type, control groups
source, number of cases and controls, and genotype fre-
quencies for cases and controls. The deviation of thegenotype frequencies in the control populations from
Hardy-Weinberg Equilibrium (HWE) was calculated
separately for each study. The control group sources
were classified as population-based controls, hospital-
based controls or mixed (both population- and hospital-
based) controls. The population ethnicity was classified
as Asian or Caucasian.
Statistical analysis
We conducted all statistical analyses using STATA soft-
ware (version 11; Stata Corporation, College Station,
Texas). All P-values were two-sided and P < 0.05 was
considered statistically significant. Odds ratios (ORs)
and 95% confidence intervals (CIs) were calculated to
assess the strength of the association between the
ABCG2 C421A polymorphism and the cancer risk. We
also examined the overall association of the A allele of
C421A with risk of cancers and compared cancer inci-
dence in homozygote (AA versus CC) model and hetero-
zygotes (AC versus CC) model, dominant (AC/AA
versus CC) model and the recessive (AA versus CC/AC)
model. The values for ORs and CIs of each individual
were considered twice. Stratified analyses were con-
ducted by cancer type, source of controls and ethnicity.
The Hardy–Weinberg equilibrium was calculated for all
the control groups of each study, and control groups of
studies that were not in HWE (p < 0.05) were excluded.
A chi-squared-based Q-statistic test was used to detect
the heterogeneity among studies. When the P-value of
the Q-test was > 0.05, which indicated a lack of hetero-
geneity among studies, a fixed-effects model (the Man-
tel–Haenszel method) was used [27]. Otherwise, if the
P-value < 0.05, the random-effects model (the DerSimo-
nian and Laird method) was used [28]. The Z test was
used to determine the significance of the combined OR
and P < 0.05 was considered statistically significant.
Sensitivity analyses to evaluate the possible biases of
the results in our meta-analyses were also performed. In
addition, we assessed the potential publication bias with
funnel plots of the effect sizes versus the standard errors
and identified the significant asymmetry by the Begg’s
test. An asymmetric plot suggests possible publication




The meta-analysis included 8 eligible articles comprising
9 case–control studies and 1 case-cohort study, for a
total of 3593 cases and 5875 controls. The study selec-
tion procedure is showed in Figure 1 and the study char-
acteristics are displayed in Table 1 [29-36]. Among all 10
studies, 2 focused only on colorectal cancer, 3 focused
on lymphoma, 3 focused on leukemia and 2 focused on
Figure 1 Flow diagram of included and excluded studies.
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were conducted in Caucasian populations, and 2 studies
were conducted in Asian populations. The control
sources were population-based in 3 studies, hospital-
based in 6 studies and both population-based and
hospital-based in 1 study. The genotype frequency data
for the C421A polymorphism in ABCG2 were extracted
from all the eligible studies, and the distributions of the
genotypes in the control populations were consistent
with Hardy-Weinberg equilibrium in all of the studies.
Quantitative data synthesis
Overall, there was evidence for an association between
decreased cancer risk and the variant genotypes in dif-
ferent genetic models and the results were listed inTable 1 Characteristics of studies included in the meta-analys
First author Year Country Ethnicity Cancer type Sourc
contro
Andersen[29] 2009 Denmark Caucasian Colorectal cancer PB
Campa[31] 2008 Germany Caucasian Colorectal cancer HB
Campa[30] 2011 Germany Caucasian Lymphoma HB
Campa[30] 2011 Germany Caucasian Lymphoma HB
Hu[33] 2007 China Asian Lymphoma MIXED
Campa[30] 2011 Germany Caucasian Leukemia HB
Muller[35] 2008 Germany Caucasian Leukemia HB
Semsei[36] 2008 Hungary Caucasian Leukemia HB
Korenaga[34] 2005 Japan Asian Renal cell carcinoma PB
Gardner[32] 2008 America Caucasian Prostate cancer PB
PB: population based; HB: hospital based; MIXED: population based and hospital baTable 2 and Figure 2. A significant decreased association
between the ABCG2 C421A genotype and cancer risk
was observed in our meta-analysis of the 10 studies (het-
erozygote model-AC versus CC: OR= 0.759, 95%CI =
0.620-0.930; dominant effects model-AA/AC versus CC:
OR=0.771, 95%CI = 0.634-0.938; additive effects model-
A allele versus C allele: OR= 0.809, 95%CI = 0.687-
0.952).
The same association was discovered in the subgroup
analyses. In the subgroup analysis by cancer types, the
ABCG2 C421A genotype significantly reduced the risk
of leukemia and other cancers in additive model (OR=
0.741, 95%CI = 0.577-0.951; OR= 0.669, 95%CI = 0.511-
0.876). Meanwhile, the variant heterozygote homozygote
genotype AC was associated with significantly decreasedis
e of
ls
Cases Controls Case Control HWE
CC CA AA CC CA AA
359 765 296 58 5 592 161 12 0.782
582 517 472 103 7 409 104 4 0.347
1067 1196 898 158 11 957 229 10 0.359
259 1156 224 33 2 921 221 14 0.856
156 376 60 80 16 181 162 33 0.703
321 1196 284 33 4 957 229 10 0.359
110 179 100 10 0 160 18 1 0.532
369 149 294 72 3 121 28 0 0.206
200 200 124 60 16 92 91 17 0.405
170 141 142 27 1 111 27 3 0.384
sed.
Table 2 Total and stratified analysis of ABCG2 C421A polymorphism on cancer risk
Variables AA versus CC AC versus CC A versus C Recessive model Dominant model
OR(95%CI) Pa OR(95%CI) Pa OR(95%CI) Pa OR(95%CI) Pa OR(95%CI) Pa
Total 1.021(0.730-1.428) 0.784 0.759(0.620-0.930) b 0.004 0.809(0.687-0.952) b 0.013 1.067(0.768-1.482) 0.935 0.771(0.634-0.938) b 0.005
Cancer type
colorectal cancer 1.073(0.491-2.344) 0.470 0.791(0.633-0.988) 0.445 0.840(0.688-1.025) 0.353 1.127(0.516-2.462) 0.494 0.806 (0.649-1.001) 0.388
lymphoma 1.200(0.736-1.958) 0.541 0.867(0.544-1.381) b 0.003 0.874(0.600-1.273) b 0.004 1.113 (0.692-1.791) 0.724 0.875(0.552-1.385) b 0.002
leukemia 1.371(0.507-3.704) 0.750 0.744(0.426-1.299) b 0.038 0.741(0.577-0.951) 0.072 1.474(0.543-4.002) 0.752 0.762(0.451-1.290) b 0.049
other 0.627(0.314-1.251) 0.419 0.574(0.407-0.808) 0.205 0.669(0.511-0.876) 0.827 0.822(0.420-1.607) 0.309 0.582 (0.420-0.807) 0.347
Source of control
Population based 0.684(0.383-1.223) 0.661 0.647(0.510-0.821) 0.289 0.710(0.582-0.867) 0.800 0.840(0.477-1.480) 0.594 0.654(0.520-0.823) 0.406
Hospital based 1.155(0.683-1.954) 0.897 0.721(0.627-0.829) 0.127 0.780(0.687-0.885) 0.158 1.225(0.724-2.075) 0.904 0.739(0.645-0.847) 0.133
HB+ PB - - - -
Ethnicity
Asian 1.040(0.633-1.707) 0.143 0.856(0.287-2.549) b 0.000 0.923(0.478-1.784)b 0.002 1.069(0.666-1.715) 0.623 0.882(0.317-2.457) b 0.000
Caucasian 1.006(0.637-1.587) 0.846 0.723(0.638-0.820) 0.280 0.773( 0.690-0.866) 0.320 1.065(0.675-1.682) 0.849 0.737(0.652-0.833) 0.293
aP value of Q-test for heterogeneity test.


















Figure 2 Forest plot of overall cancer risk associated with the ABCG2 C421A polymorphism: A allele versus C allele. (additive, random-
effects model).
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CC:OR= 0.791, 95%CI = 0.633-0.988) compared with the
wild-type homozygote genotype CC; When the studies
were stratified by the source of controls, associations
were observed in both studies with population-based
controls (OR= 0.710, 95%CI = 0.582-0.867) and those
with hospital-based controls (OR= 0.780, 95%CI = 0.687-
0.885). In the dominant effects model and heterozygote
model, this association was also present and the result
was listed in Table 2; In the analysis stratified by popula-
tion, the C421A polymorphism in ABCG2 was signifi-
cantly correlated with cancer risk in Caucasian
populations (OR=0.773, 95%CI = 0.690-0.866) but not in
Asian populations (OR=0.923, 95%CI = 0.478-1.784)
populations in additive genetic model, however, in theFigure 3 Influence analysis for A allele versus C allele in the overall m
on the summary OR. The middle vertical axis shows the overall OR and the
omitting each study (left column) in turn. Meta-analysis random-effects estdominant effect model and heterozygote model, no sig-
nificant association between the ABCG2 polymorphism
and low cancer risk was found in Asian in comparison
to in Caucasian and the result was presented listed in
Table 2.
Heterogeneity analysis
There was significant heterogeneity among studies in the
additive model, dominant effect model and heterozygote
model (2AA+AC versus 2CC+AC, AA+AC versus CC,
AC versus CC) of the C421A polymorphism in ABCG2.
However, in the other model comparisons (AA versus
CC, AA versus AC/CC), heterogeneity was not found
(Table 2). We assessed additive model comparison, het-
erozygote comparison and dominant model comparisoneta-analysis. This figure illustrates the influence of individual studies
two vertical axes indicate the 95% CI. Results were computed by
imates were used.
Figure 4 Begg’s funnel plot for publication bias test (AA/AC VS
CC); each point represents a separate study for the indicated
association. Log(OR): natural logarithm of OR. Horizontal line
represents size of effect.
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source, sample size and HWE in controls. However, we
did not observe any contribution to the substantial
heterogeneity.
Sensitivity analyses
We performed sensitivity analyses by sequentially re-
moving individual eligible study (Figure 3). The results
indicated that the overall significance of the ORs was
not altered by any single study in the genetic models for
the C421A polymorphism in ABCG2 and cancer suscep-
tibility which suggested the stability and liability of our
overall results.
Publication bias
We assessed the potential publication biases of the
included studies using the Begg’s funnel plot and Egger’s
test (Figure 4), the result showed no significant evidence
of publication bias (t = 0.15, P = 0.884 for dominant
effects model).
Discussion
Carcinogenesis is a complex process that involves both
genetic and environmental factors and their interactions
[1]. Since the genetic factors such as single nucleotide
substitutions and gross chromosomal aberrations
were considered to make more contribution to tumori-
genesis, numerous studies focused on the candidate-
polymorphism approach notably increased the number
of associations between polymorphism and cancer risk
[37]. Recently, increasing attention has been paid to the
relationships between genetic variants such as SNPs and
cancer risk. Plentiful epidemiological evidence demon-
strated that the process of detoxification and elimination
of xenobiotics was involved in the development of can-
cers [14,16,17].The ABCG2 gene (also known as BCRP), located on
chromosomal locus 4q22, encodes an ABC half-
transporter protein that localizes to the plasma membrane.
ABCG2 works as a multidrug efflux pump, influen-
cing the metabolism of multiple substances including
anticancer drugs and carcinogenic xenobiotics [10-13].
The abnormal distribution of carcinogenic xenobiotics
may increase the local carcinogen burden of specific
cells and organelles [38] and cause tumorigenesis. To
date, there have been a great deal of epidemiological
studies to investigate the association between the C421
polymorphism in ABCG2 and the risk of various types
of cancers, however, the exact relationship between can-
cer susceptibility and the ABCG2 C421A polymorphism
remains unclear. To address this issue, we performed a
synthetic analysis based on data collected from all stud-
ies that have investigated the relationship between this
polymorphism and cancer risk.
Generally speaking, our meta-analysis, which included
3593 cases and 5875 controls, revealed a significant as-
sociation between the ABCG2 C421A allele and
decreased cancer risk in different genetic model (hetero-
zygote model-AC versus CC: OR=0.759, 95%CI = 0.620-
0.930; dominant effects model-AA/AC versus CC: OR=
0.771, 95%CI = 0.634-0.938; additive effects model-A al-
lele versus C allele: OR= 0.809, 95%CI = 0.687-0.952).
This result provides convincing evidence that the C421A
polymorphism in ABCG2 might protect against cancer
development. Moreover, this effect persisted when the
studies were stratified by ethnicity classification. When
stratified by cancer, source of controls and ethnicity clas-
sification, the C421A polymorphism of ABCG2 was also
an important protective factor against cancer develop-
ment in the subgroups studied.
However, the studies published by Hu and Korenaga
[33,34] were contradictory to ours, indicating that car-
riers of the A allele of ABCG2 C421A had an increased
risk of cancer. Three explanations may have contributed
to this disparity in results. One possible explanation
could be that the different environmental factors or dif-
ferent sample size of the two studies may influence the
function of the ABCG2 C421A for developing cancer.
Another possible explanation for this observation was
that gene-gene interactions and gene-environment inter-
actions may be responsible for this discrepancy. More-
over, the overlapping function of the other ABC
transporters may be involved in. However, the precise
mechanism of the contradictory effect remains unsure,
further studies may help to clarify this issue.
It is well known that four capital factors of genome-
wide association studies (GWAS) consisting of models
of the allelic architecture of common diseases, sample
size, map density and sample-collection biases need to
be taken into account in order to optimize the cost
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[39]. To validate the strong associations between the
C421A polymorphism in ABCG2 and the cancer risk,
Daniele Campa and his colleagues extracted date from
two previous GWAS on CLL (chronic lymphocytic
leukemia) [40,41]. Based on the genotyping information
from them, allelic odds ratios were calculated to confirm
the relationship between the genetic polymorphisms and
CLL risk. Their results identified a statistically significant
association between the risk of CLL and the ABCG2
C421A genotype [30]. Furthermore, these authors also
performed a meta-analysis of 3 studies [30,40,41], which
provided evidence of a significant association between
decreased cancer risk and the ABCG2 C421A poly-
morphism. Our findings were consistent with these
results [30].
Heterogeneity is a potential problem which might in-
fluence the interpretation of the results. In our meta-
analysis, significant heterogeneity between studies was
present in additive model, heterozygote model and dom-
inant model (Table 2). The heterogeneity reduced or dis-
appeared when the studies were stratified by cancer
type, source of controls and ethnicity, however, we did
not find adequate evidence to determine which of them
contributed most to the substantial heterogeneity. The
publication bias for the association between this poly-
morphism and cancer risk was not observed in our
meta-analysis.
Some possible limitations of our meta-analysis should
be acknowledged and taken into consideration. First,
detailed information, such as the mean age and sex of
the case and control populations, was not available in all
of the selected studies, which limited further analyses.
Second, the results may be influenced by the lack of
observations regarding gene-gene and gene-environment
interactions even different polymorphic loci of the same
gene. Third, the conclusions had the possibility to be
disturbed due to the existence of overlapping function of
the other ABC transporters. Fourth, the numbers of
published studies were not sufficiently enough for a
comprehensive analysis on different types of cancer. For
example, there were no published data for gastric cancer,
nervous system neoplasm and lung cancer with associ-
ation of ABCG2 C421A published up to now; we did
not posses enough statistical power to detect the precise
association. More studies are needed to explore the rela-
tionship between C421A polymorphism in ABCG2 and
cancer risk. In spite of these potential limitations, our
meta-analysis also has many advantages. Firstly, suffi-
cient date was extracted form well-selected studies, pro-
viding good statistical power for this meta-analysis.
Secondly, studies included in our meta-analysis con-
tained available genotype frequency and the distribution
of the genotypes in the control population of all thestudies were consistent with Hardy-Weinberg equilib-
rium. Thirdly, no publication bias was detected among
the pooled results.
Conclusions
In conclusion, this meta-analysis demonstrates that the
ABCG2 C421A polymorphism is associated with a
decreased risk of cancer and is likely a protective factor
against cancer development. However, further studies on
the relationship between this polymorphism and cancer
risk are warranted.
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